| Dr David G Shapnick, MD | |
|
401 S Alabama St, Butte, MT 59701-2315 | |
| (406) 782-3808 | |
| (406) 782-3802 |
| Full Name | Dr David G Shapnick |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 401 S Alabama St, Butte, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245280205 | NPI | - | NPPES |
| 0065790 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 7021 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David G Shapnick, MD 305 Aspen Way, Butte, MT 59701-3992 Ph: (406) 782-3808 | Dr David G Shapnick, MD 401 S Alabama St, Butte, MT 59701-2315 Ph: (406) 782-3808 |
News Archive
McMaster University researchers who analyzed thousands of documents covering a 300-year span of plague outbreaks in London, England, have estimated that the disease spread four times faster in the 17th century than it had in the 14th century.
Laboratory Corporation of America Holdings announced today the nationwide availability of a new FDA cleared risk stratification tool (ROMA, Risk of Ovarian Malignancy Algorithm) that combines the results for Fujirebio HE4, Abbott's ARCHITECT CA 125 II, and menopausal status into a numerical score that, along with clinical and radiological evaluation, can aid in evaluating whether a woman over the age of 18 who presents with an ovarian mass and for whom surgery is planned is at high or low likelihood of finding malignancy on surgery.
Inoviem Scientific, a Contract Research Biotech (CRB) company today announces that it has received additional funding of €545,000 ($611,000) from French public investment bank bpifrance. The company leverages two proprietary technologies to offer pharmaceutical players increased speed and enhanced safety at all stages of drug development; from drug discovery (the identification of secondary targets and detection of potential adverse effects, etc.) through to clinical trials (with patient stratification and identification of biomarkers, etc.).
MiddleBrook Pharmaceuticals, Inc. has entered into an asset purchase agreement with Victory Pharma, Inc. for the sale of substantially all of its assets, and assumption of trade sales and certain other liabilities, of the Company for approximately $17.1 million (the "Acquisition").
› Verified 8 days ago
Bartholomew Andrew Martyak, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3417 Busch St, Butte, MT 59701 Phone: 406-541-3937 Fax: 406-541-1810 | |
Dr. Robert Ian Noble, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 832 S Montana St, Butte, MT 59701 Phone: 406-723-4004 | |
Clay Daniel Holley, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3417 Busch St, Butte, MT 59701 Phone: 406-494-3145 | |
Dr. Richard T Tschetter, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 832 S Montana St, Butte, MT 59701 Phone: 406-723-4004 Fax: 406-782-4567 |